IntelGenx Technologies (IGX) Set to Announce Quarterly Earnings on Thursday

IntelGenx Technologies (CVE:IGX) is scheduled to announce its earnings results after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of C($0.04) per share for the quarter.

IntelGenx Technologies (CVE:IGX) last issued its quarterly earnings results on Thursday, August 9th. The company reported C($0.05) earnings per share for the quarter, hitting the Zacks’ consensus estimate of C($0.05). The business had revenue of C$0.30 million for the quarter, compared to analysts’ expectations of C$0.13 million.

Shares of IGX stock traded down C$0.03 during trading hours on Tuesday, reaching C$0.81. 8,200 shares of the company’s stock were exchanged, compared to its average volume of 73,126. IntelGenx Technologies has a 1 year low of C$0.78 and a 1 year high of C$2.36.

WARNING: “IntelGenx Technologies (IGX) Set to Announce Quarterly Earnings on Thursday” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/11/06/intelgenx-technologies-igx-set-to-announce-quarterly-earnings-on-thursday.html.

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat cognitive impairment and Alzheimer's disease.

Featured Article: The benefits and drawbacks of dollar cost averaging

Earnings History for IntelGenx Technologies (CVE:IGX)

Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply